A branched-chain amino acid composition for skeletal muscle energy supply and its application

Abstract

This invention discloses a branched-chain amino acid composition for skeletal muscle energy supply and its application, belonging to the field of amino acid composition preparation. The branched-chain amino acid composition for skeletal muscle energy supply includes component A and component B; component B is a solution of component A; component A includes the following components: stearic acid-modified magnesium citrate-lysine hydrochloride complex and betaine-branched-chain amino acid eutectic porous particles; the amount of stearic acid-modified magnesium citrate-lysine hydrochloride complex is 12-15% of the mass of the betaine-branched-chain amino acid eutectic porous particles; component B includes the following components: water, mannitol, and an amphiphilic surfactant. This invention solves the problem that, as the dissolution rate of branched-chain amino acid compositions increases, their hydrophilicity and hygroscopic properties also significantly increase, increasing the difficulty of storing branched-chain amino acid compositions and reducing the shelf life of branched-chain amino acid compositions after opening.

Description

Technical Field

[0001] This invention belongs to the field of amino acid composition preparation, and relates to a branched-chain amino acid composition for skeletal muscle energy supply and its application. Background Technology

[0002] Branched-chain amino acids (BCAAs) are a collective term for leucine, isoleucine, and valine. BCAAs are the main amino acids providing energy to skeletal muscle, accounting for approximately 60% of the total energy supply from amino acids. Even at rest, BCAAs contribute about 14% of the energy from oxidative processes in human skeletal muscle. BCAAs can be taken 30-60 minutes before or after training to promote muscle regeneration and synthesis. The recommended dosage is 5-10 grams per dose.

[0003] Leucine, isoleucine, and valine have low solubility in water. Therefore, various types of fast-dissolving branched-chain amino acid (BCAA) compositions have been obtained through surfactant treatment, significantly improving the dissolution rate of BCAA compositions in water. The dissolved BCAAs are more easily absorbed. However, as the dissolution rate of BCAA compositions increases, their hydrophilicity and hygroscopic properties also increase significantly. This requires strict requirements for the sealing of BCAA composition packaging, increasing packaging difficulty. Moreover, for large-capacity packaging products, the shelf life after opening is short because the BCAA compositions are prone to moisture absorption and deterioration after opening. Summary of the Invention

[0004] The purpose of this invention is to provide a branched-chain amino acid composition for skeletal muscle energy supply and its application, which solves the problem that as the dissolution rate of branched-chain amino acid compositions increases, their hydrophilicity and hygroscopic properties also increase significantly, increasing the difficulty of preserving branched-chain amino acid compositions and reducing the shelf life of branched-chain amino acid compositions after opening.

[0005] The technical solution adopted in the present invention is as follows:

[0006] A branched-chain amino acid composition for skeletal muscle energy supply, comprising component A and component B; wherein component B is a solution of component A;

[0007] Component A comprises the following components: stearic acid-modified magnesium citrate-lysine hydrochloride complex and betaine-branched amino acid eutectic porous particles; the amount of stearic acid-modified magnesium citrate-lysine hydrochloride complex is 12-15% of the mass of betaine-branched amino acid eutectic porous particles;

[0008] Component B includes the following components: water, mannitol, and amphiphilic surfactant.

[0009] This application first improves the water solubility of branched-chain amino acids (BCAAs) and ensures their basic rapid solubility by preparing betaine-branched-chain amino acid eutectic porous particles. Secondly, a stearic acid-modified magnesium citrate-lysine hydrochloride complex is added to fill the pores of the betaine-BCAA eutectic porous particles, thus hydrophobically modifying the particles and reducing their hydrophilic and hygroscopic properties during storage. To balance the rapid solubility in the solvent with the hydrophobic and moisture-proof properties under storage conditions, this invention includes component B, which is mainly composed of water and contains mannitol and an amphiphilic surfactant.

[0010] After the stearic acid-modified magnesium citrate-lysine hydrochloride complex is surrounded by component B, the interfacial tension between the stearic acid-modified magnesium citrate-lysine hydrochloride complex and the aqueous phase is reduced under the action of the amphiphilic surfactant, thus lowering the osmotic resistance of the aqueous phase and increasing the wettability of the stearic acid-modified magnesium citrate-lysine hydrochloride complex. With sufficient contact between the magnesium citrate-lysine hydrochloride complex and the aqueous phase, under the bridging effect of the surfactant and accompanied by the high permeability of the mannitol aqueous solution, a locally enriched ionic solution is formed in the aqueous phase. The formation of the ionic solution enhances the permeability of water and increases the osmotic pressure. As water-soluble substances dissolve, the stearic acid-modified magnesium citrate-lysine hydrochloride complex dissociates, and the undissolved substances dissolve under the action of the surfactant. Under the action of [unclear], the insoluble substances are mainly small amounts of stearic acid and stearate, forming a uniform dispersion system in component B. This only affects the transparency and clarity of the entire system, without affecting the dissolution and absorption of branched-chain amino acids, and will not have any impact on the body. During the dissociation process of the stearic acid-modified magnesium citrate-lysine hydrochloride complex, ion solution enrichment will be formed in the pores of the betaine-branched-chain amino acid eutectic porous particles, increasing the osmotic pressure of water and further promoting water to enter the gaps of the porous particles. Water penetration into the gaps of the porous particles causes the porous particle structure to break and fully contact and dissolve with the fast-dissolving betaine-branched-chain amino acid eutectic particles, achieving the effect of low hydrophilicity and hygroscopicity in storage environment (including natural environment containing air and moisture) and rapid dissolution in the solution.

[0011] The stearic acid-modified magnesium citrate-lysine hydrochloride complex in this application is filled into betaine-branched amino acid eutectic porous particles. It does not seal the betaine-branched amino acid eutectic porous particles and make them completely waterproof. This application only ensures that the branched amino acid composition will not absorb moisture and deteriorate for a longer period of time than the prior art when exposed to an environment with humidity between 60-80%.

[0012] After being encapsulated by the aqueous phase in the highly permeable component B, the betaine-branched amino acid eutectic porous particles partially self-dissolve. With the decrease in interfacial tension and local enrichment of the stearic acid-modified magnesium citrate-lysine hydrochloride complex in component B, not only is the disintegration of the stearic acid-modified magnesium citrate-lysine hydrochloride complex achieved, but the permeability of the aqueous phase in the betaine-branched amino acid eutectic porous particles is also enhanced, further increasing the dissolution rate of the betaine-branched amino acid eutectic porous particles. Therefore, this application achieves both rapid dissolution of the branched amino acid composition and a longer shelf life under natural conditions than existing technologies, reducing the sealing requirements for airtight storage.

[0013] Stearic acid hydrophobic layers are generally quite dense. Therefore, in order to ensure that the hydrophobic layer can disintegrate upon dissolution, this application uses a hydrophobic-hydrophilic modified composite, namely a stearic acid-modified magnesium citrate-lysine hydrochloride complex, to replace the stearic acid hydrophobic layer. Under the action of surfactants, the hydrophobic-hydrophilic modified composite utilizes the dissolution of the hydrophilic layer to achieve the disintegration of the hydrophobic layer.

[0014] Furthermore, the betaine-branched amino acid eutectic porous particles are obtained by the following method: betaine and branched amino acid complex in a mass ratio of 1:1 are subjected to an antisolvent method to obtain betaine-branched amino acid eutectic slurry, and the eutectic slurry is subjected to three-stage drying and fluidization treatment to obtain betaine-branched amino acid eutectic porous particles.

[0015] Furthermore, the branched-chain amino acid complex includes leucine, isoleucine, and valine.

[0016] Furthermore, the mass ratio of leucine, isoleucine, and valine is 2:1:1.

[0017] Furthermore, component B, by total weight, comprises the following components: 85-89 wt% water, 8-10 wt% mannitol, and 3-5 wt% amphiphilic surfactant.

[0018] Furthermore, the ratio of component A to component B is 5-7.5:200g / ml, meaning that 5-7.5g of component A requires 200ml of component B to dissolve.

[0019] Furthermore, the stearic acid-modified magnesium citrate-lysine hydrochloride composite is prepared by the following method: magnesium citrate and lysine hydrochloride are mixed in deionized water at a mass ratio of 1:1, stirred and heated for 2-4 hours, then stearic acid and sodium dodecyl sulfate are added to continue the reaction, followed by cooling, filtration, washing, drying, and pulverization to obtain the stearic acid-modified magnesium citrate-lysine hydrochloride composite; wherein, the amount of stearic acid added is 20-30 wt% of the total mass of magnesium citrate and lysine hydrochloride, and the amount of sodium dodecyl sulfate added is 10-12 wt% of stearic acid.

[0020] Furthermore, the amphiphilic surfactant is a lecithin surfactant.

[0021] Furthermore, the three-stage drying of the eutectic slurry includes the following steps:

[0022] First stage: Under a vacuum of 0.2 mbar, for 8 hours, the temperature is raised from -30℃ to -10℃;

[0023] Level 2: Maintain a constant temperature of -5℃ for 2 hours;

[0024] Level 3: 12 hours, temperature rise from -5℃ to 25℃.

[0025] The aforementioned branched-chain amino acid composition for skeletal muscle energy supply is used to prepare nutrients for skeletal muscle energy supply.

[0026] In summary, due to the adoption of the above technical solution, the beneficial effects of the present invention are:

[0027] 1. The present invention provides a branched-chain amino acid composition for skeletal muscle energy supply. By preparing betaine-branched-chain amino acid eutectic porous particles, the water solubility of branched-chain amino acids is improved, ensuring the basic rapid solubility of branched-chain amino acids. On this basis, a stearic acid-modified magnesium citrate-lysine hydrochloride complex is added. The stearic acid-modified magnesium citrate-lysine hydrochloride complex fills the pores of the betaine-branched-chain amino acid eutectic porous particles, thereby hydrophobically modifying the porous particles and reducing their hydrophilicity and hygroscopic properties during storage, thus solving the problem of moisture absorption during storage.

[0028] 2. In order to balance the two properties of rapid solubility in solvent and hydrophobicity and moisture resistance under storage conditions, this invention has formulated component B. Component B uses water as the main solvent and adds mannitol and amphiphilic surfactant. Component B can cause the stearic acid modified magnesium citrate-lysine hydrochloride complex to disintegrate, destroy the hydrophobic sites, expose the solubility point, and ensure the rapid dissolution of branched amino acids.

[0029] 3. The betaine-branched amino acid eutectic of the present invention is a porous particle. The porous structure can not only accommodate the stearic acid modified magnesium citrate-lysine hydrochloride complex, but also help to improve the dissolution rate of branched amino acids. Attached Figure Description

[0030] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings used in the embodiments will be briefly described below. It should be understood that the following drawings only show some embodiments of the present invention and should not be regarded as a limitation of the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort, wherein:

[0031] Figure 1 This is a photograph of component A.

[0032] Figure 2 This is a microscopic image of the particle surface of component A. Detailed Implementation

[0033] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only for explaining the invention and are not intended to limit the invention; that is, the described embodiments are merely some embodiments of the invention, and not all embodiments. The components of the embodiments of the invention described and shown in the accompanying drawings can generally be arranged and designed in various different configurations.

[0034] Therefore, the following detailed description of the embodiments of the invention provided in the accompanying drawings is not intended to limit the scope of the claimed invention, but merely to illustrate selected embodiments of the invention. All other embodiments obtained by those skilled in the art based on the embodiments of the invention without inventive effort are within the scope of protection of the invention.

[0035] It should be noted that relational terms such as "first" and "second" are used merely to distinguish one entity or operation from another, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Furthermore, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such a process, method, article, or apparatus. Without further limitations, an element defined by the phrase "comprising one..." does not exclude the presence of other identical elements in the process, method, article, or apparatus that includes said element.

[0036] The features and performance of the present invention will be further described in detail below with reference to embodiments.

[0037] This invention provides a branched-chain amino acid composition for skeletal muscle energy supply, comprising component A and component B; wherein component B is a solution of component A.

[0038] Component A comprises the following components: stearic acid-modified magnesium citrate-lysine hydrochloride complex and betaine-branched amino acid eutectic porous particles; the amount of stearic acid-modified magnesium citrate-lysine hydrochloride complex is 12-15% of the mass of betaine-branched amino acid eutectic porous particles; the particle size range of the stearic acid-modified magnesium citrate-lysine hydrochloride complex particles is within the pore size range of the betaine-branched amino acid eutectic porous particles; the stearic acid-modified magnesium citrate-lysine hydrochloride complex can fill the pores of the betaine-branched amino acid eutectic porous particles; the lysine hydrochloride is L-lysine hydrochloride.

[0039] Component B includes the following components: water, mannitol, and amphiphilic surfactant.

[0040] The betaine-branched amino acid eutectic porous particles are obtained by the following method: a betaine and branched amino acid complex at a mass ratio of 1:1 are subjected to an anti-solvent method to obtain a betaine-branched amino acid eutectic slurry. The eutectic slurry is then subjected to three-stage drying followed by fluidization treatment to obtain the betaine-branched amino acid eutectic porous particles. The three-stage drying includes the following steps:

[0041] First stage: Under a vacuum of 0.2 mbar, for 8 hours, the temperature is raised from -30℃ to -10℃;

[0042] Level 2: Maintain a constant temperature of -5℃ for 2 hours;

[0043] Level 3: 12 hours, temperature rise from -5℃ to 25℃.

[0044] The branched-chain amino acid complex includes leucine, isoleucine, and valine, wherein the mass ratio of leucine, isoleucine, and valine is 2:1:1.

[0045] Component B, by total weight, includes the following components: 85-89 wt% water, 8-10 wt% mannitol, and 3-5 wt% amphiphilic surfactant.

[0046] The ratio of component A to component B is 5-7.5:200g / ml, and 200ml of component B is required to dissolve every 5-7.5g of component A.

[0047] The stearic acid-modified magnesium citrate-lysine hydrochloride composite was prepared by the following method: magnesium citrate and lysine hydrochloride were mixed in deionized water at a mass ratio of 1:1, stirred and heated for 2-4 hours, then stearic acid and sodium dodecyl sulfate were added to continue the reaction, followed by cooling, filtration, washing, drying, and pulverization to obtain the stearic acid-modified magnesium citrate-lysine hydrochloride composite; wherein, the amount of stearic acid added was 20-30 wt% of the total mass of magnesium citrate and lysine hydrochloride, and the amount of sodium dodecyl sulfate added was 10-12 wt% of stearic acid. The sodium dodecyl sulfate was food grade.

[0048] The amphiphilic surfactant is a lecithin surfactant.

[0049] The aforementioned branched-chain amino acid composition for skeletal muscle energy supply is used to prepare nutrients for skeletal muscle energy supply.

[0050] Examples 1-9:

[0051] Based on the above, Examples 1-9 each provide a branched-chain amino acid composition for skeletal muscle energy supply. The difference lies in the different component ratios of components A and B, and the different amounts of stearic acid added in the stearic acid-modified magnesium citrate-lysine hydrochloride complex. The preparation methods are all the same. The differences are shown in Table 1.

[0052] Examples 1-9 provide a branched-chain amino acid composition for skeletal muscle energy supply, comprising component A and component B; component B is a solution of component A; the addition ratio of component A to component B is 5:200 g / ml, and 200 ml of component B is required to dissolve every 5 g of component A.

[0053] Component A comprises the following components: stearic acid-modified magnesium citrate-lysine hydrochloride complex and betaine-branched amino acid eutectic porous particles; the particle size range of the stearic acid-modified magnesium citrate-lysine hydrochloride complex particles is within the pore size range of the betaine-branched amino acid eutectic porous particles; the stearic acid-modified magnesium citrate-lysine hydrochloride complex can fill the pores of the betaine-branched amino acid eutectic porous particles;

[0054] Component B comprises the following components: water, mannitol, and an amphiphilic surfactant; the branched-chain amino acid complex comprises leucine, isoleucine, and valine, wherein the mass ratio of leucine, isoleucine, and valine is 2:1:1; and the amphiphilic surfactant is a lecithin surfactant.

[0055] A method for preparing a branched-chain amino acid composition for skeletal muscle energy supply includes the following steps:

[0056] S1. Preparation of Component A: 30% of the total amount of stearic acid modified magnesium citrate-lysine hydrochloride complex is first dry-mixed with betaine-branched amino acid eutectic porous particles to obtain a premix; then the remaining stearic acid modified magnesium citrate-lysine hydrochloride complex is dispersed in anhydrous ethanol containing 10% by mass of food-grade sodium dodecyl sulfate (anhydrous ethanol is the total amount measured) to obtain a suspension of stearic acid modified magnesium citrate-lysine hydrochloride complex; the premix is ​​placed in a fluidized bed, and hot air at 37°C is introduced for fluidization, while the stearic acid modified magnesium citrate-lysine hydrochloride complex suspension is sprayed in simultaneously, and finally dried to obtain Component A, which is then sealed and stored.

[0057] S2. Preparation of Component B: Dissolve mannitol in deionized water at 50°C and stir until completely dissolved; cool to 30°C, add an amphiphilic surfactant and homogenize to obtain Component B, which is then sealed and stored. Component A and Component B are separately packaged and stored according to their usage ratios. Component B and Component A are generally packaged separately in bags, while Component A can also be packaged in large-capacity cans.

[0058] A physical image of component A prepared within the scope of Example 6 is shown below. Figure 1 As shown, the particles are uniform and free of impurities visible to the naked eye. The SEM image of the particle surface is shown below. Figure 2 As shown, there are obvious pores and filling material.

[0059] Table 1. Component ratios for Examples 1-9:

[0060] .

[0061] Examples 10 and 11:

[0062] Examples 10-11 provide branched-chain amino acid compositions for skeletal muscle energy supply. The difference from Example 6 is that the addition ratio of component A and component B is different, as shown in Table 2.

[0063] Table 2. The dosage ratio of component A and component B in Examples 6 and 10-11:

[0064] .

[0065] Comparative Example 1:

[0066] Based on Example 6, this comparative example differs from Example 6 in that it does not include component B, and the solution for component A is deionized water.

[0067] Comparative Example 2:

[0068] Based on Example 6, this comparative example differs from Example 6 in that component B does not include mannitol.

[0069] Comparative Example 3:

[0070] Based on Example 6, this comparative example differs from Example 6 in that component B does not include an amphiphilic surfactant.

[0071] Comparative Example 4:

[0072] Based on Example 6, this comparative example differs from Example 6 in that: component A includes the following components: stearic acid modified calcium carbonate complex and betaine-branched amino acid eutectic porous particles.

[0073] Comparative Example 5:

[0074] Based on Example 6, this comparative example differs from Example 6 in that: component A includes the following components: magnesium citrate-lysine hydrochloride complex (without stearic acid modification) and betaine-branched amino acid eutectic porous particles.

[0075] Comparative Example 6:

[0076] Based on Example 6, this comparative example differs from Example 6 in that component A does not include the stearic acid-modified magnesium citrate-lysine hydrochloride complex.

[0077] Comparative Example 7:

[0078] Based on Example 6, the difference between this comparative example and Example 6 is that component A includes stearic acid and betaine-branched amino acid eutectic porous particles.

[0079] Comparative Example 8:

[0080] Based on Example 6, the difference between this comparative example and Example 6 is that component A includes stearic acid modified magnesium citrate-lysine hydrochloride complex and branched-chain amino acid porous particles (excluding betaine).

[0081] Comparative Example 9:

[0082] Based on Example 6, this comparative example differs from Example 6 in that component A does not include lysine hydrochloride.

[0083] Comparative Example 10:

[0084] Based on Example 6, this comparative example differs from Example 6 in that component A does not include magnesium citrate.

[0085] Comparative Example 11:

[0086] Based on Example 6, this comparative example differs from Example 6 in that the betaine-branched amino acid eutectic porous particles are obtained by the following method: betaine and branched amino acid complex in a mass ratio of 1:1 are subjected to an antisolvent method to obtain betaine-branched amino acid eutectic slurry. The eutectic slurry is dried and then fluidized to obtain betaine-branched amino acid eutectic porous particles. The drying process does not include the first stage: 8 hours under a vacuum of 0.2 mbar, with the temperature rising from -30°C to -10°C.

[0087] Comparative Example 12:

[0088] Based on Example 6, the difference between this comparative example and Example 6 is that the drying process in the preparation method of the betaine-branched amino acid eutectic porous particles does not include the second stage: constant temperature at -5℃ for 2 hours.

[0089] Experimental Example 1:

[0090] The dissolution time of components A and B after mixing in the corresponding proportions in Examples 1-11 and Comparative Examples 1-12 under stirring and the macroscopic characterization of the dissolved solution were tested respectively. The test method was the prior art, and the results are shown in Table 3.

[0091] The branched-chain amino acid composition in this application will not completely dissolve. A small amount of substances that are insoluble in the aqueous phase will form a uniform and stable dispersion system. Therefore, the dissolution described throughout this application does not mean that all substances are completely dissolved and present a completely clear state, but rather a milky white, semi-transparent, uniformly dispersed system without any visible precipitates.

[0092] According to the ratio of component A to component B, mix component A and component B, and record the time when the solution is uniform, milky white and translucent, with no visible particles, under magnetic stirring (200 rpm). This time is recorded as the dissolution time of component A in component B, and the state at this point is the macroscopic characterization of the solution.

[0093] Table 3. Dissolution time of branched-chain amino acid compositions and macroscopic characterization of the solution:

[0094] .

[0095] Key parameters affecting dissolution time include: the proportion of stearic acid-modified magnesium citrate-lysine hydrochloride complex, the stearic acid ratio, the content of amphiphilic surfactant, and the mannitol content. This application coordinates the values ​​of these factors to achieve optimal synergistic effects, resulting in a dissolution rate superior to existing methods. Existing fast-dissolving branched-chain amino acids can be found in patent 202211617864.9, etc. Although the solution of this invention is not clear, its dissolution time is superior to existing technologies. Without affecting the dissolution of branched-chain amino acids, it can be understood that the difference in the solution of this application is merely a difference in physical characteristics and does not affect the normal absorption of branched-chain amino acids.

[0096] Experimental Example 2:

[0097] The hygroscopicity of component A in Examples 1-3 and Comparative Examples 4-12 was tested. 5g of component A was placed in a constant humidity chamber at 60%, 70%, and 80% humidity and 25°C. The hygroscopic rate was recorded daily, and a hygroscopic rate >5% was considered failure. The time of failure was also recorded in days. The results are shown in Table 4. The control group consisted of the mixed fast-dissolving branched-chain amino acids prepared in Example 5 of patent CN202211617864.9.

[0098] Table 4 Hygroscopicity of Component A:

[0099] .

[0100] The factors affecting the hygroscopicity of component A mainly include the proportion of stearic acid-modified magnesium citrate-lysine hydrochloride complex in component A, the proportion of stearic acid in the complex, the eutectic structure, and the filling effect between the eutectic structure and the complex. A higher proportion of stearic acid in component A does not necessarily mean better hydrophobicity. It is necessary to comprehensively consider the hydrophobic properties of the complex itself (affected by the proportion of stearic acid) and its pore-filling effect with porous particles (mainly affected by the proportion of stearic acid-modified magnesium citrate-lysine hydrochloride complex). Therefore, based on the data in Tables 3 and 4, Example 6 can be considered a preferred solution. In Table 4, data >3.5-4 refers to values ​​greater than 3.5 and less than or equal to 4, and this is used as a reference. Other data are expressed in the same way. >3.5-4 (excluding 4) means greater than 3.5 and less than 4.

[0101] Experimental Example 3: The content of branched-chain amino acids in the solid substance obtained after centrifugation of the homogeneous liquid obtained by mixing components A and B in Examples 1-11 was detected. The results are shown in Table 5.

[0102] Table 5. Content of branched-chain amino acids in the solids after solid-liquid separation:

[0103] .

[0104] Experimental Example 4:

[0105] Microbiological testing and toxicity tests were conducted on the homogeneous liquid obtained by mixing components A and B in Examples 1-11. No Cronobacter spp., Staphylococcus aureus, Salmonella, or Escherichia coli were detected. The acute oral toxicity test according to GB 15193.3-2014 National Food Safety Standard was passed, and the product was found to be non-toxic.

[0106] The above description is merely a preferred embodiment of the present invention and is not intended to limit the scope of protection of the present invention. Any modifications, equivalent substitutions, and improvements made by those skilled in the art within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. A branched-chain amino acid composition for skeletal muscle energy supply, characterized in that: It includes component A and component B; component B is a solution of component A. Component A comprises the following components: stearic acid-modified magnesium citrate-lysine hydrochloride complex and betaine-branched amino acid eutectic porous particles; the amount of stearic acid-modified magnesium citrate-lysine hydrochloride complex is 12-15% of the mass of betaine-branched amino acid eutectic porous particles; Component B includes the following components: water, mannitol, and amphiphilic surfactant; The betaine-branched amino acid eutectic porous particles are obtained by the following method: betaine and branched amino acid complex in a mass ratio of 1:1 are subjected to an antisolvent method to obtain betaine-branched amino acid eutectic slurry. The eutectic slurry is then subjected to three-stage drying and fluidization treatment to obtain betaine-branched amino acid eutectic porous particles. The three-stage drying process includes the following steps: First stage: Under a vacuum of 0.2 mbar, for 8 hours, the temperature is raised from -30℃ to -10℃; Level 2: Maintain a constant temperature of -5℃ for 2 hours; Level 3: 12 hours, temperature rise from -5℃ to 25℃; The particle size range of the stearic acid-modified magnesium citrate-lysine hydrochloride composite particles is within the pore size range of the betaine-branched amino acid eutectic porous particles, and the stearic acid-modified magnesium citrate-lysine hydrochloride composite particles fill the pores of the betaine-branched amino acid eutectic porous particles.

2. The branched-chain amino acid composition for skeletal muscle energy supply according to claim 1, characterized in that: The branched-chain amino acid complex includes leucine, isoleucine, and valine.

3. The branched-chain amino acid composition for skeletal muscle energy supply according to claim 2, characterized in that: The mass ratio of leucine, isoleucine, and valine is 2:1:

1.

4. The branched-chain amino acid composition for skeletal muscle energy supply according to claim 1, characterized in that: Component B, by total weight, includes the following components: 85-89 wt% water, 8-10 wt% mannitol, and 3-5 wt% amphiphilic surfactant.

5. The branched-chain amino acid composition for skeletal muscle energy supply according to claim 1, characterized in that: The ratio of component A to component B is 5-7.5:200g / ml, and 200ml of component B is required to dissolve every 5-7.5g of component A.

6. The branched-chain amino acid composition for skeletal muscle energy supply according to claim 1, characterized in that: The stearic acid-modified magnesium citrate-lysine hydrochloride composite was prepared by the following method: magnesium citrate and lysine hydrochloride were mixed in deionized water at a mass ratio of 1:1, stirred and heated for 2-4 hours, then stearic acid and sodium dodecyl sulfate were added to continue the reaction, followed by cooling, filtration, washing, drying, and pulverization to obtain the stearic acid-modified magnesium citrate-lysine hydrochloride composite; wherein, the amount of stearic acid added was 20-30 wt% of the total mass of magnesium citrate and lysine hydrochloride, and the amount of sodium dodecyl sulfate added was 10-12 wt% of stearic acid.

7. The branched-chain amino acid composition for skeletal muscle energy supply according to claim 1, characterized in that: The amphiphilic surfactant is a lecithin surfactant.

8. A branched-chain amino acid composition for skeletal muscle energy supply according to any one of claims 1-7, characterized in that, Nutrients used to prepare energy for skeletal muscle.

Images